Changes in Laboratory Indexes for Multiple Myeloma Patients Before and After Autologous Stem Cell Transplant

References

• Wang S, Xu L, Feng J, et al. Prevalence and incidence of multiple myeloma in urban area in china: a national population-based analysis. Front Oncol. 2020;9:1513. doi:10.3389/fonc.2019.01513
   PubMed Web of Science ®Google Scholar
• Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004–2017: an observational study. J Hematol Oncol. 2019;12(1):22. doi:10.1186/s13045-019-0706-9
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905. doi:10.1056/NEJMoa1402888
   PubMed Web of Science ®Google Scholar
• van de Donk NW, van der Holt B, Minnema MC, et al. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the Phase 3, randomized controlled trial. Lancet Haematol. 2018;5(10):e479–e492. doi:10.1016/S2352-3026(18)30149-2
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529–534. doi:10.1182/blood-2011-01-332320
   PubMed Web of Science ®Google Scholar
• Samer A, Bashir Q, Denái R, et al. Long-term survival for myeloma after autologous stem cell transplantation. Blood. 2020;136(Supplement 1):23–24.
   Google Scholar
• Minakata D, Fujiwara SI, Murahashi R, et al. Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: a retrospective analysis. Leuk Res. 2022;112:106750. doi:10.1016/j.leukres.2021.106750
   PubMed Web of Science ®Google Scholar
• Di Lernia G, Leone P, Solimando AG, et al. Bortezomib treatment modulates autophagy in multiple myeloma. J Clin Med. 2020;9(2):552. doi:10.3390/jcm9020552
   PubMed Web of Science ®Google Scholar
• Zhang X, Duan J, Wen Z, et al. Are the derived indexes of peripheral whole blood cell counts (NLR, PLR, LMR/MLR) clinically significant prognostic biomarkers in multiple myeloma? A systematic review and meta-analysis. Front Oncol. 2021;11:766672. doi:10.3389/fonc.2021.766672
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. doi:10.4065/78.1.21
   PubMed Web of Science ®Google Scholar
• Sun C, Ye JN, Wang H, et al. Prognostic value of red blood cell distribution width in senile patients with non-transplanted multiple myeloma. Zhong guo Shi Yan Xue Ye Xue Za Zhi. 2019;27:115–122.
   PubMedGoogle Scholar
• Kelkitli E, Atay H, Cilingir F, et al. Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio. Ann Hematol. 2014;93(5):841–846. doi:10.1007/s00277-013-1978-8
   PubMed Web of Science ®Google Scholar
• Sweiss K, Calip GS, Johnson JJ, Rondelli D, Patel PR. Pretransplant hemoglobin and creatinine clearance correlate with treatment-free survival after autologous stem cell transplantation for multiple myeloma. Bone Marrow Transplant. 2019;54(12):2081–2087. doi:10.1038/s41409-019-0628-8
   PubMed Web of Science ®Google Scholar
• Plasma Cell Disease Group. Chinese Society of Hematology, Chinese Medical Association, Chinese Myeloma Committee-Chinese Hematology Association. Chinese guidelines of autologous stem cell transplantation for multiple myeloma (2021). Chin J Hematol. 2021;42:353–357. doi:10.3760/cma.j.issn.0253-2727.2021.05.001
   Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126(20):2284–2290. doi:10.1182/blood-2015-05-643320
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28–35. doi:10.1001/jamaoncol.2016.3160
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18F] fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35(25):2911–2918. doi:10.1200/JCO.2017.72.2975
   PubMed Web of Science ®Google Scholar
• Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23(1):10–24. doi:10.1038/leu.2008.259
   PubMed Web of Science ®Google Scholar
• Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):44. doi:10.1038/s41408-019-0205-9
   PubMedGoogle Scholar
• Kumar SK, Dispenzieri A, Fraser R, et al. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia. 2018;32(4):986–995. doi:10.1038/leu.2017.331
   PubMed Web of Science ®Google Scholar
• Ludwig H, Khayat D, Giaccone G, et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer. 2005;104(9):1794–1807. doi:10.1002/cncr.21414
   PubMed Web of Science ®Google Scholar
• Kane RC, Bross PF, Farrell AT, et al. Velcade: u.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508–513. doi:10.1634/theoncologist.8-6-508
   PubMed Web of Science ®Google Scholar
• Dolan RD, Laird BJA, Horgan PG, et al. The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review. Crit Rev Oncol Hematol. 2018;132:130–137. doi:10.1634/theoncologist.8-6-508
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Sakamoto Y, Nakagawa S, et al. Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection. Int J Clin Oncol. 2017;22(4):740–748. doi:10.1007/s10147-017-1102-5
   PubMed Web of Science ®Google Scholar
• Zhao QT, Yuan Z, Zhang H, et al. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3720 patients. Int J Cancer. 2016;139(1):164–170. doi:10.1002/ijc.30060
   PubMed Web of Science ®Google Scholar
• Chao B, Ju X, Zhang L, Xu X, Zhao Y. A novel prognostic marker Systemic Inflammation Response Index (SIRI) for operable cervical cancer patients. Front Oncol. 2020;10:766. doi:10.3389/fonc.2020.00766
   PubMed Web of Science ®Google Scholar
• Ren L, Xu J, Li J, et al. A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients [published online ahead of print, 2023 Jan 13]. Clin Exp Med. 2023. doi:10.1007/s10238-023-00992-8.
   Web of Science ®Google Scholar
• Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16(4):309–323. doi:10.1016/j.ccr.2009.08.019
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nishiwaki K, Nagao R, et al. Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis. Int J Hematol. 2021;114(5):599–607. doi:10.1007/s12185-021-03201-y
   PubMed Web of Science ®Google Scholar
• Sweiss K, Lee J, Mahmud N, et al. Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant. Bone Marrow Transplant. 2020;55(1):199–206. doi:10.1038/s41409-019-0681-3
   PubMed Web of Science ®Google Scholar
• Sun J, Chen X, Gao P, et al. Can the neutrophil to lymphocyte ratio be used to determine gastric cancer treatment outcomes? A systematic review and meta-analysis. Dis Markers. 2016;2016:7862469. doi:10.1155/2016/7862469
   PubMed Web of Science ®Google Scholar
• Romano A, Laura Parrinello N, Cerchione C, et al. The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents. Blood Cancer J. 2017;7(12):649. doi:10.1038/s41408-017-0019-6
   PubMedGoogle Scholar
• Dosani T, Covut F, Beck R, Driscoll JJ, de Lima M, Malek E. Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer J. 2017;7(6):e579. doi:10.1038/bcj.2017.60
   PubMedGoogle Scholar